INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

Ingo K. Mellinghoff,Martin J. van den Bent,Jennifer Leigh Clarke,Elizabeth A. Maher,Katherine B. Peters,Mehdi Touat,John Frederick de Groot,Macarena I. de la Fuente,Isabel Arrillaga-Romany,Wolfgang Wick,Benjamin M. Ellingson,Steven Schoenfeld,Feng Tai,Kha Le,Min Lu,Lori Steelman,Islam Hassan,Shuchi Sumant Pandya,Patrick Y. Wen,Timothy F. Cloughesy

INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

2020

TPS2574Background: Low-grade gliomas (LGGs; WHO grade II) are incurable and ultimately progress to high-grade gliomas. The current treatment options consist of surgery followed by observation (“wat...

Keywords:

Gastroenterology
double blind
Isocitrate dehydrogenase
Internal medicine
Mutation
Grade II Glioma
in patient
Indigo
Pathology
IDH1
Placebo
Medicine
treatment options

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations